View source for 18282749. COMPOSITIONS AND METHODS FOR TARGETING INFLAMMATORY OR ACTIVATED CELLS AND TREATING OR AMELIORATING INFLAMMATORY CONDITIONS AND PAIN simplified abstract (The Regents of the University of California)

=COMPOSITIONS AND METHODS FOR TARGETING INFLAMMATORY OR ACTIVATED CELLS AND TREATING OR AMELIORATING INFLAMMATORY CONDITIONS AND PAIN=


==Organization Name==

[[:Category:The Regents of the University of California|The Regents of the University of California]]


[[Category:The Regents of the University of California]]

==Inventor(s)==

[[:Category:Yury Miller of San Diego CA (US)|Yury Miller of San Diego CA (US)]][[Category:Yury Miller of San Diego CA (US)]]

[[:Category:Soo-Ho Choi of San Diego CA (US)|Soo-Ho Choi of San Diego CA (US)]][[Category:Soo-Ho Choi of San Diego CA (US)]]

==COMPOSITIONS AND METHODS FOR TARGETING INFLAMMATORY OR ACTIVATED CELLS AND TREATING OR AMELIORATING INFLAMMATORY CONDITIONS AND PAIN - A simplified explanation of the abstract==


This abstract first appeared for US patent application 18282749 titled 'COMPOSITIONS AND METHODS FOR TARGETING INFLAMMATORY OR ACTIVATED CELLS AND TREATING OR AMELIORATING INFLAMMATORY CONDITIONS AND PAIN

'''Simplified Explanation:'''
The patent application describes methods for modifying amino acid sequences to increase the expression of ApoA-I Binding Protein for treating various conditions such as neuropathic pain, CNS inflammation, neurodegenerative diseases, and cardiovascular issues.

'''Key Features and Innovation:'''
* Modification of amino acid sequences to enhance ApoA-I Binding Protein expression
* Treatment of neuropathic pain, inflammation, neurodegenerative diseases, and cardiovascular conditions
* Administration of pharmaceutical compositions containing recombinantly modified APOA1BP polypeptide

'''Potential Applications:'''
The technology can be applied in the treatment of neuropathic pain, CNS inflammation, neurodegenerative diseases like Alzheimer's, hyperalgesia, migraines, glaucoma, lung inflammation, asthma, viral infections, and cardiovascular diseases.

'''Problems Solved:'''
The technology addresses the need for effective treatments for various painful conditions, inflammatory diseases, neurodegenerative disorders, and cardiovascular issues by enhancing the expression of ApoA-I Binding Protein.

'''Benefits:'''
* Improved treatment outcomes for neuropathic pain, inflammation, and neurodegenerative diseases
* Potential reduction in symptoms of hyperalgesia, migraines, glaucoma, and asthma
* Enhanced management of cardiovascular conditions and inflammatory diseases

'''Commercial Applications:'''
The technology has potential commercial applications in the pharmaceutical industry for developing novel treatments for a wide range of conditions, including neuropathic pain, inflammation, neurodegenerative diseases, and cardiovascular issues.

'''Prior Art:'''
Prior research may exist on the role of ApoA-I Binding Protein in various disease conditions and the potential therapeutic benefits of modulating its expression.

'''Frequently Updated Research:'''
Researchers may be conducting ongoing studies on the efficacy of recombinantly modified APOA1BP polypeptide in treating different diseases and conditions.

'''Questions about the Technology:'''
1. What are the specific mechanisms through which the modified APOA1BP polypeptide exerts its therapeutic effects?
2. Are there any potential side effects or limitations associated with the administration of pharmaceutical compositions containing the recombinantly modified APOA1BP polypeptide?


==Original Abstract Submitted==

Provided are methods for modification of amino acid sequence and increasing levels of expression of ApoA-I Binding Protein to treat: a neuropathic pain, a CNS inflammation, an allodynia, a post nerve injury pain, a post-surgical pain, a chemotherapeutic-induced peripheral neuropathy, a neurodegeneration, including for example, a neurodegenerative disease or condition such as Alzheimer's disease, a hyperalgesia, primary headaches such as migraines and cluster headaches, glaucoma or other inflammatory diseases of the eye, lung inflammation, asthma, HIV infection, vascular inflammation, atherosclerosis and cardiovascular disease. Provided are methods comprising administering pharmaceutical compositions comprising a recombinantly modified APOA1BP polypeptide to treat a neuropathic pain, an allodynia, a hyperalgesia, a neurodegenerative disease, a primary headache such as a migraine, glaucoma, lung inflammation and asthma, acute respiratory distress syndrome (ARDS), sepsis, viral infection, including influenza, coronavirus (for example, COVID-19) or HIV infection, or its comorbidities, and/or vascular inflammation, atherosclerosis and cardiovascular disease.



[[Category:C12N9/90]]
[[Category:A61K38/52]]
[[Category:A61P11/06]]
[[Category:A61P25/00]]
[[Category:A61P27/06]]
[[Category:CPC_C12N9/90]]